PSI is a leading full-service global Contract Research Organization (CRO). The company specializes in delivering pivotal Phase 2 and Phase 3 clinical trials on time and on budget, with predictable patient enrollment across multiple therapeutic areas.
PSI focuses on a wide range of therapeutic areas including Oncology, Gastroenterology (GI), Hematology, Cell and Gene Therapy, Neurology, Infectious Diseases, Radiopharmaceuticals, and Respiratory diseases, among others.
The company leverages advanced platforms like Visional for clinical trial feasibility analysis and Synetic for site intelligence and study acceleration, aiming to protect trials from delays and budget overruns through data-driven solutions.
